User contributions for Alen Antony

21:2521:25, 21 May 2024 diff hist +824‎ N Pegunigalsidase alfa-iwxj ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=pegunigalsidase alfa-iwxj |indicationType=treatment |indication=Fabry's disease in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis. |blackBoxWarningTitle=HYPERSENSITIVITY REACTIONS including Anaphylaxis |blackBoxWarningBody=Patients may experience hypersensitivity reaction including a..."

03:5603:56, 20 May 2024 diff hist +1,712‎ Leniolisib ‎No edit summary current
03:3803:38, 20 May 2024 diff hist +1,404‎ Leniolisib ‎No edit summary

14:4114:41, 16 May 2024 diff hist +2‎ Leniolisib ‎No edit summary
14:4014:40, 16 May 2024 diff hist −2‎ Leniolisib ‎No edit summary
14:4014:40, 16 May 2024 diff hist +359‎ N Leniolisib ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=leniolisib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. |adverseReactions=headache, sinusitis, and {{atopic dermatitis}}. |brandNames=JOENJA }}"
14:3414:34, 16 May 2024 diff hist +1,803‎ Trofinetide ‎No edit summary current
14:1914:19, 16 May 2024 diff hist −1‎ Trofinetide ‎No edit summary Tag: Manual revert
03:4703:47, 16 May 2024 diff hist +1‎ Trofinetide ‎No edit summary
03:4603:46, 16 May 2024 diff hist +2,158‎ Trofinetide ‎No edit summary
03:2903:29, 16 May 2024 diff hist +912‎ Trofinetide ‎No edit summary
03:0903:09, 16 May 2024 diff hist +1,072‎ Trofinetide ‎No edit summary

04:4004:40, 15 May 2024 diff hist +41‎ Trofinetide ‎No edit summary
04:4004:40, 15 May 2024 diff hist +135‎ Trofinetide ‎No edit summary
04:2804:28, 15 May 2024 diff hist +1,695‎ Fezolinetant ‎No edit summary current
04:2104:21, 15 May 2024 diff hist +1,499‎ Fezolinetant ‎No edit summary
03:4403:44, 15 May 2024 diff hist +174‎ Fezolinetant ‎No edit summary
03:3703:37, 15 May 2024 diff hist +19‎ Fezolinetant ‎No edit summary
02:4602:46, 15 May 2024 diff hist +589‎ Fezolinetant ‎No edit summary
02:2402:24, 15 May 2024 diff hist +234‎ Fezolinetant ‎No edit summary
01:3201:32, 15 May 2024 diff hist +512‎ Fezolinetant ‎No edit summary
01:0901:09, 15 May 2024 diff hist +59‎ Fezolinetant ‎No edit summary

23:4823:48, 13 May 2024 diff hist +84‎ N Fezolinetant ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}"
23:4623:46, 13 May 2024 diff hist +3,844‎ Nirsevimab-alip ‎No edit summary current
14:5014:50, 13 May 2024 diff hist +1,936‎ N Nirsevimab-alip ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection..."

19:1119:11, 10 May 2024 diff hist +829‎ Sotagliflozin ‎No edit summary current
18:1218:12, 10 May 2024 diff hist +833‎ Sotagliflozin ‎No edit summary
17:5417:54, 10 May 2024 diff hist +545‎ Sotagliflozin ‎No edit summary
17:4617:46, 10 May 2024 diff hist +744‎ Sotagliflozin ‎No edit summary
17:1217:12, 10 May 2024 diff hist +672‎ Sotagliflozin ‎No edit summary

23:5923:59, 9 May 2024 diff hist +19‎ Sotagliflozin ‎No edit summary
15:1715:17, 9 May 2024 diff hist +1,230‎ Sotagliflozin ‎No edit summary
04:5704:57, 9 May 2024 diff hist +418‎ N Sotagliflozin ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=sotagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=prophylaxis |indication=heart failure in patients with risk of heart failure, type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. |adverseReactions=urinary tract infection, volume depletion, diarrhea, and hypoglycemia. }}"

04:1304:13, 8 May 2024 diff hist +2,528‎ Zuranolone ‎No edit summary current
03:4803:48, 8 May 2024 diff hist +3,227‎ Zuranolone ‎No edit summary

20:1820:18, 7 May 2024 diff hist +1,017‎ Zuranolone ‎No edit summary
17:2717:27, 7 May 2024 diff hist +836‎ N Zuranolone ‎ Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad..."

Navigation menu